MOTS-C vs Tesamorelin for performance
Short answer: For performance, users rate them about the same: 85% report improvement with MOTS-C (34 reports) and 88% with Tesamorelin (25 reports).
MOTS-C has 0 meta-analyses and 4 randomized trials on PubMed; Tesamorelin has 3 and 21.
Based on 213 reports about MOTS-C and 265 about Tesamorelin. Not medical advice.
| MOTS-C Peptide | Tesamorelin Peptide | |
|---|---|---|
| Users say it helped | 49%helped100 reports · high confidence | 58%helped119 reports · high confidence |
| Verdict | Mixed | Mixed |
| Research | CResearch: Limited | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 4 | 3 / 21 |
| Mainly used for | ||
| Weight loss % reporting improvement | 86% (14) | 95% (82) |
| Energy % reporting improvement | 83% (78) | 100% (5) |
| Performance % reporting improvement | 85% (34) | 88% (25) |
| Sleep % reporting improvement | 0% (5) | 70% (20) |
| Recovery % reporting improvement | — | 100% (10) |
| Common side effects | insomnia, injection site, dizziness, jitteriness | water retention, allergic reaction, anaphylaxis, swelling |
| Typical dose reported | Not listed | Not listed |
“Taking these makes me feel wildly energetic all day—zero afternoon slumps, and my endurance during cardio feels bottomless.”
However, limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution. Future research should evaluate extended treatment duration, dose-response relationships, and patient-reported outcomes to establish comprehensive clinical utility.
J Int Assoc Provid AIDS Care, 2026 ↗“I also added Tesamorelin 2 months in due to the harder time sleeping on Retatrutide and wanting to accelerate the burn of my visceral fats (2mg 5x a week). Worked like magic for me.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate